Catyalyst Pharmaceutical (CPRX) Posts Q1 Loss of 7c/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Catyalyst Pharmaceutical (CPRX) Posts Q1 Loss of 7c/Share

Catalyst Pharmaceutical Partners Announces First Quarter 2014 Financial Results and Provides Corporate Update

May 16, 2014 8:03 AM EDT

CORAL GABLES, Fla., May 16, 2014 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Catalyst) (Nasdaq: CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, today reported financial results for the first quarter ended March 31, 2014.

Catalyst's lead clinical candidate, Firdapse, is in Phase 3 development in the United States for Lambert-Eaton Myasthenic Syndrome (LEMS), a rare autoimmune disorder characterized by muscle weakness of the limbs. Firdapse is approved in the E.U., where it is marketed by BioMarin Pharmaceutical.

"This year to date has... More